Novel Use of Brigatinib in Patients with Advanced Solid Tumors with ALK or ROS1 Alterations (Phase II)

Solid Tumors
Sameek Roychowdhury, MD, PhD
The Ohio State University


Dr. Roychowdhury and team are examining the use of Brigatinib, a chemotherapy drug that is in pill form, for solid tumors with a rare genetic mutation. This trial is using telemedicine to recruit and onboard patients, ensuring that patients will have very limited (if any) face-to-face encounters with the clinical trial staff at The Ohio State University in Columbus, Ohio. Instead, patients receive their chemotherapy drugs via the mail and will coordinate with their local oncology offices with day-to-day assistance. This approach empowers patients to participate in the clinical trial in a manner that protects both the patients and the investigators. If the trial is successful, not only will this demonstrate the effectiveness decentralized medicine, but it may find an effective treatment for patients with rare solid tumors with ALK or ROS1 mutations.